<DOC>
	<DOCNO>NCT02383940</DOCNO>
	<brief_summary>This Phase 2 study intend demonstrate superiority Sotagliflozin versus placebo A1C reduction Week 12 young adult patient T1DM poor glycemic control current insulin regimen .</brief_summary>
	<brief_title>Efficacy Safety Sotagliflozin Young Adult Patients With Type 1 Diabetes Mellitus Elevated Hemoglobin A1C</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Patient give write informed consent Young adult patient ≥18 ≤30 year old Screening , confirm diagnosis T1DM make least 1 year prior informed consent Patients treat insulin insulin analogue deliver via CSII MDI At Screening , must A1C ≥9.0 % Must willing able perform SMBG complete study diary Females childbearing potential must use adequate method contraception negative pregnancy test Any prior use LX4211/Sotagliflozin Use antidiabetic agent insulin insulin analogue time screen Use SGLT inhibitor within 8 week prior start placebo Runin Period Chronic systemic corticosteroid use Type 2 diabetes , severely uncontrolled diabetes mellitus determine Investigator History DKA nonketotic hyperosmolar state within 6 month prior Screening Visit History severe hypoglycemic event within 1 month prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>